Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 1.1% - Time to Buy?

Key Points

• Armata Pharmaceuticals shares rose 1.1% to $3.78, although trading volume was 77% below the stock’s average daily volume. The company has a market capitalization of approximately $140.5 million.
• Analyst sentiment remains positive, with two Buy ratings and one Hold rating producing a consensus “Moderate Buy” rating and an average price target of $15.00.
• Armata reported a quarterly loss of $0.27 per share, beating the expected $0.44 loss, while revenue of $2.51 million exceeded the $0.40 million estimate. The clinical-stage biotech is developing bacteriophage therapies for drug-resistant bacterial infections.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report)'s stock price was up 1.1% during trading on Monday. The company traded as high as $3.85 and last traded at $3.78. 85,688 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 367,441 shares. The stock had previously closed at $3.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Armata Pharmaceuticals in a research note on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

Armata Pharmaceuticals Stock Up 1.1%

The firm has a market cap of $140.54 million, a price-to-earnings ratio of -0.50 and a beta of 1.34. The stock has a fifty day moving average price of $4.84 and a 200-day moving average price of $7.21.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.17. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.40 million. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%. As a group, research analysts expect that Armata Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ARMP. Bank of America Corp DE purchased a new position in Armata Pharmaceuticals during the second quarter worth about $73,000. Madison Asset Management LLC purchased a new stake in Armata Pharmaceuticals in the 2nd quarter valued at approximately $13,654,000. BlackRock Inc. purchased a new stake in Armata Pharmaceuticals in the 2nd quarter valued at approximately $3,629,000. Deutsche Bank AG acquired a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $78,000. Finally, Bank of New York Mellon Corp acquired a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $193,000. 3.57% of the stock is currently owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata's approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria.

The company's pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.